Regulatoriskt pressmeddelande2025-12-11 10:45Diagonal Bio intends to submit a formal application for bankruptcy
Regulatoriskt pressmeddelande2025-10-31 08:00Diagonal Bio publishes interim report for the third quarter of 2025
Pressmeddelande2025-10-13 09:00Diagonal Bio launches new website to reflect commercial focus on the Animal Health segment
Pressmeddelande2025-10-03 11:30Diagonal Bio initiates collaboration with SVA on evaluation of coronavirus in horses
Regulatoriskt pressmeddelande2025-09-23 11:15Diagonal Bio expands horse testing panel to detect Equine Herpesvirus type 2
Regulatoriskt pressmeddelande2025-08-22 08:00Diagonal Bio publishes interim report for the second quarter of 2025
Pressmeddelande2025-07-07 13:00Diagonal Bio AB files patent application for Novel Computational Method that significantly improves LAMP primer design
Regulatoriskt pressmeddelande2025-06-25 13:00The Board of Directors of Diagonal Bio carries out a directed issue to underwriters in connection with exercise of warrants of series TO 2
Regulatoriskt pressmeddelande2025-06-19 13:40Diagonal Bio receives SEK 3.6 million through exercise of warrants of series TO 2
Regulatoriskt pressmeddelande2025-06-17 18:47Update regarding large shareholder’s exercise of warrants of series TO 2
Regulatoriskt pressmeddelande2025-06-17 08:30Diagonal Bio expands equine panel with addition of strangles
Regulatoriskt pressmeddelande2025-06-13 08:00Last day of trading in Diagonal Bio’s warrants of series TO 2 is 16 June 2025
Regulatoriskt pressmeddelande2025-06-09 14:00Svea Bank AB invests SEK 0.5 million in Diagonal Bio AB through the exercise of warrants of series TO 2